A study to evaluate the safety and physiological effects of a single dose of AZD7442 in children.  

Status: Closed for Recruitment

Population: Paediatric

Disease Group: COVID-19

Funder: AstraZeneca AB

Sponsor: AstraZeneca AB

Principal Investigator: Dr Simon Drysdale

Study Aims

The purpose of this study is to learn more about an experimental drug called AZD7442 (the ‘study drug’) and to find out if it may help prevent and treat COVID-19 and its associated health problems in children and adolescents.

What participating in the study involves

The purpose of the study is to learn more about an experimental drug called AZD7442 (the ‘study drug’) and to find out if it may help prevent and treat COVID-19 at its associated health problems in children and adolescents. ‘Experimental’ means that the drug is being used in research studies like this and we continue learning about the drug efficacy, effects and safety of it. 

The screening period can last up to 7 days. Each participant will undergo tests to check they are suitable to participate, including a PCR test to confirm whether they are SARS-CoV-2 negative.  

 If screening criteria are met, each participant will be given a single dose of AZD7442 and monitored for 15 months. During this time, each participant will attend the study site for 8 visits to undergo tests* to see how they are responding to AZD7442. 

*The study doctor will explain what these tests are before a decision is made to take part.